Transcode Therapeutics (RNAZ) Change in Cash (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Change in Cash came in at -$5.0 million in Q1 2026, down 186.45% YoY from $5.8 million in Q1 2025, and down 133.24% on a QoQ basis from $15.0 million in Q4 2025.
Transcode Therapeutics (RNAZ) Change in Cash (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Change in Cash data on file, last reported at -$5.0 million in Q1 2026.
- Quarterly Change in Cash fell 186.45% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 80.97% YoY) and the FY2025 annual result came in at $12.0 million, up 294.37% from the prior year.
- Change in Cash eased to -$5.0 million in Q1 2026, from $15.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $15.0 million in Q4 2025 to a low of -$5.0 million in Q1 2026.
- A 5-year average of -$470023.9 and a median of -$3.3 million in 2023 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2022 — Change in Cash plunged 17503.72% — and 2025, when it surged 280.61%.
- Tracing RNAZ's Change in Cash over 5 years: stood at -$3.8 million in 2022, then dropped by 22.58% to -$4.7 million in 2023, then soared by 183.99% to $3.9 million in 2024, then surged by 280.61% to $15.0 million in 2025, then plunged by 133.24% to -$5.0 million in 2026.
- The last three Change in Cash figures came in at -$5.0 million (Q1 2026), $15.0 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.98 Mn |
| Dec 31, 2025 | 14.98 Mn |
| Sep 30, 2025 | -4.54 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Mar 31, 2025 | 5.76 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | -4.69 Mn |
| Sep 30, 2023 | 3.88 Mn |
| Jun 30, 2023 | 1.95 Mn |
| Mar 31, 2023 | -3.35 Mn |
| Dec 31, 2022 | -3.82 Mn |
| Sep 30, 2022 | -4.65 Mn |
| Jun 30, 2022 | -3.41 Mn |
| Mar 31, 2022 | -3.97 Mn |
| Dec 31, 2021 | -1.67 Mn |
| Sep 30, 2021 | 22.42 Mn |
| Jun 30, 2021 | -19,395.00 |